William Blair analyst Andrew Brackmann has reiterated their bullish stance on GH stock, giving a Buy rating today.
Andrew Brackmann has given his Buy rating due to a combination of factors including positive fourth-quarter updates and promising future projections for Guardant Health. The company’s revenue guidance for 2025 slightly surpasses market expectations, and the outlook for their Shield product appears optimistic, which suggests potential upside in the guidance figures. Despite the significant rise in share value since the previous quarter, Brackmann believes there is still room for growth in the coming months.
Additionally, the precision oncology sector of Guardant Health is expected to see accelerated growth, with rising volumes and average selling prices, alongside new datasets to bolster reimbursement efforts. The company is on track to reduce cash burn significantly, with a target to reach free cash flow breakeven excluding screening by the fourth quarter of 2025. While there are some uncertainties regarding the screening segment, Brackmann acknowledges the potential for exceeding the current guidance, which could attract more investor interest and support the stock’s momentum.
In another report released today, Barclays also maintained a Buy rating on the stock with a $60.00 price target.
Based on the recent corporate insider activity of 137 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year.